报价延迟最少15分钟:2026/03/09 10:01 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.335 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.09/0.88
|
|
企业价值
4.93B
|
| 资产负债 |
|
每股账面净值
0.87
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
634.21M
|
|
每股收益
1.19
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
